DEA license offers Cure hemp-based CBD manufacturing

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Aleksandr_Kravtsov)
(Image: Getty/Aleksandr_Kravtsov)

Related tags: CBD, Manufacturing, facility, DEA, California, hemp, Dosage forms

Cure Pharma expands its DEA license to include authorization to manufacture both cannabis plant extracts and CBD within the scope of its patent portfolio.

The manufacturer's original license with the US Drug Enforcement Administration (DEA) enabled the company to manufacture products containing synthetic tetrahydrocannabinol (THC). With the expanded authorization, the company can now manufacture products containing synthetic cannabidiol (CBD), as well as extracts from the cannabis plant, such as hemp-based CBD.

With this expanded license, Cure has the capability to manufacture its dosage form, Curefilm​, which enables the delivery of cannabinoids with increased bioavailability and allows for precision dosing using both synthetic and cannabis-based extracts.

The dosage form technology using cannabis extracts is patented by Cure, covering the extraction and fractioning of bioactive cannabinoid molecules, such as THC and CBD, from the cannabis plant and the enabling integration process of these molecules into the dosage form.

A spokesperson for Cure Pharma told us that Curefilm is a sublingual dosage form that can be loaded with multiple active ingredients at high doses. Additionally, it drives higher absorption of lipophilic molecules and offers increased bioavailability, as well as greater palatability.

“Most oral dosage forms are oil capsules and solutions – there is a market opportunity for more sophisticated dosage forms that enable multiple routes of administration and precise dosing, such as Cure’s oral film technology,”​ the spokesperson told us.

The company explained that whether hemp-derived CBD will be regulated as a drug or dietary supplement, the market for hemp-derived CBD will grow between an estimated $646m (€568.7m) on the low side to $22bn by 2022 on the high side.

With the broadened license, the company states it can expand upon the potential formulations it can develop with CBD and cannabis extracts. 

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more